BioVie Reports Success in Early Parkinson's Disease Clinical Trial

Carson City, Friday, 7 August 2026.
BioVie’s Phase 2 trial of bezisterim successfully met its goals, demonstrating significant improvements in both motor and non-motor Parkinson’s symptoms while shifting 283 disease-related proteins toward disease-slowing patterns.